CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 in New York.
The company's presentation will be available via video webcast starting September 8, 2025, at 7:00 AM ET for registered attendees. Management will also conduct one-on-one meetings with qualified investors during the conference. The webcast recording will remain accessible on the company's website for 90 days after the event.
CNS Pharmaceuticals (NASDAQ:CNSP), azienda biofarmaceutica impegnata nello sviluppo di terapie per tumori cerebrali e del sistema nervoso centrale, sarà presente al H.C. Wainwright 27th Annual Global Investment Conference dall'8 al 10 settembre 2025 a New York.
La presentazione sarà fruibile tramite video webcast a partire dall'8 settembre 2025 alle 07:00 ET per i partecipanti registrati. La direzione terrà inoltre incontri individuali con investitori qualificati durante la conferenza. La registrazione del webcast resterà disponibile sul sito della società per 90 giorni dopo l'evento.
CNS Pharmaceuticals (NASDAQ:CNSP), una compañía biofarmacéutica centrada en desarrollar tratamientos para cánceres cerebrales y del sistema nervioso central, participará en el H.C. Wainwright 27th Annual Global Investment Conference del 8 al 10 de septiembre de 2025 en Nueva York.
La presentación estará disponible vía video webcast a partir del 8 de septiembre de 2025 a las 7:00 AM ET para los asistentes registrados. La dirección también mantendrá reuniones individuales con inversores calificados durante la conferencia. La grabación del webcast permanecerá accesible en la web de la compañía durante 90 días tras el evento.
CNS Pharmaceuticals (NASDAQ:CNSP))는 뇌 및 중추신경계 암 치료제 개발에 주력하는 바이오제약사로, 2025년 9월 8일부터 10일까지 뉴욕에서 열리는 H.C. Wainwright 27th Annual Global Investment Conference에 참가합니다.
회사의 발표는 등록된 참석자를 대상으로 2025년 9월 8일 오전 7:00(ET)부터 비디오 웹캐스트로 시청하실 수 있습니다. 경영진은 컨퍼런스 기간 중 적격 투자자와의 일대일 미팅도 진행합니다. 웹캐스트 녹화는 행사 종료 후 90일간 회사 웹사이트에서 계속 이용할 수 있습니다.
CNS Pharmaceuticals (NASDAQ:CNSP), une société biopharmaceutique dédiée au développement de traitements pour les cancers du cerveau et du système nerveux central, participera au H.C. Wainwright 27th Annual Global Investment Conference du 8 au 10 septembre 2025 à New York.
La présentation sera accessible en webcast vidéo à partir du 8 septembre 2025 à 7h00 ET pour les participants inscrits. La direction tiendra également des réunions individuelles avec des investisseurs qualifiés pendant la conférence. L'enregistrement du webcast restera disponible sur le site de la société pendant 90 jours après l'événement.
CNS Pharmaceuticals (NASDAQ:CNSP), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Therapien für Hirn- und ZNS-Krebsarten spezialisiert hat, wird vom 8. bis 10. September 2025 in New York beim H.C. Wainwright 27th Annual Global Investment Conference vertreten sein.
Die Unternehmenspräsentation steht registrierten Teilnehmern ab dem 8. September 2025 um 07:00 Uhr ET per Video-Webcast zur Verfügung. Das Management wird während der Konferenz außerdem Einzelgespräche mit qualifizierten Investoren führen. Die Aufzeichnung des Webcasts bleibt 90 Tage nach der Veranstaltung auf der Website des Unternehmens abrufbar.
- None.
- None.
HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 8, 2025, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company's website (cnspharma.com). The webcast replay will be archived for 90 days following the event.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
When is CNS Pharmaceuticals (CNSP) presenting at the H.C. Wainwright Conference 2025?
How can investors access CNS Pharmaceuticals' (CNSP) H.C. Wainwright conference presentation?
How long will CNS Pharmaceuticals' (CNSP) conference presentation be available for viewing?
What type of meetings will CNS Pharmaceuticals (CNSP) management conduct at the conference?
